Conatus Pharmaceuticals Inc (CNAT) 5.92 $CNAT
Conatus to Present at BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York at 8:30 a.m. ET on Tuesday, February 10, 2015. An audio webcast and a copy of the presentation will be available live and archived in the Investor Center of the company's website at http://ir.conatuspharma.com/events.cfm.
CNAT: 5.92 (+0.10)
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 6.80 (+0.03), RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
ResMed (RMD) Beats Q2 Earnings & Revenues, Margin Falls - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 8:00AM CST
Currently, ResMed (RMD) is engaged in executing its three horizons growth strategy of improving patient quality-of-life, lowering healthcare costs, and preventing chronic disease progression.
ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), CNAT: 5.92 (+0.10), RMD: 66.25 (+0.79)
Medtronic Unveils MiniMed 640G Advanced Glucose Sensor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 12:20PM CST
Medtronic's (MDT) MiniMed 640G System acts like an artificial pancreas by managing hypoglycemia and rebound hyperglycemia
ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), MDT: 75.26 (+0.33), CNAT: 5.92 (+0.10)
Conatus Pharmaceuticals Implements Veeva Vault eTMF and QualityDocs to Speed Global Clinical Trials of New Biologic Emricasan
Business Wire - Thu Jan 22, 6:00AM CST
To improve visibility, control, and collaboration for its ongoing and planned clinical trials, San Diego-based biotech Conatus Pharmaceuticals selected cloud-based Veeva Vault eTMF and Veeva Vault QualityDocs - applications for the management of clinical study and quality and development documentation, respectively. As the company expanded its network of external partners across a growing number of sites worldwide, Conatus sought a fully paperless solution to reduce costs and provide an efficient way for all parties - including a largely mobile clinical workforce - to access content. With Veeva Vault eTMF and Veeva Vault QualityDocs, Conatus has gained a single, authoritative source for verified, current documents, streamlining information sharing across the enterprise.
VEEV: 30.12 (+0.17), CNAT: 5.92 (+0.10)
Abaxis' (ABAX) VetScan Feline Test Wins USDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 12:50PM CST
Abaxis' novel test kit is used to identify the presence of FeLV antigen and FIV antibodies in blood samples of cats.
ICUI: 88.98 (+0.42), ABAX: 60.93 (+0.65), CNAT: 5.92 (+0.10), VASC: 26.44 (+0.79)
Trial Data Add Little Clarity And Much Confusion To Conatus
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 21, 9:39AM CST
CNAT: 5.92 (+0.10)
St. Jude Medical (STJ) Announces Preliminary Q4 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 11:00AM CST
St. Jude Medical, Inc.'s (STJ) fourth-quarter revenues are estimated to grow 1% year over year to around $1.44 billion, which is in line with the current Zacks Consensus Estimate.
ICUI: 88.98 (+0.42), CNAT: 5.92 (+0.10), STJ: 67.48 (+0.65), OSUR: 8.13 (+0.06)
Regado Bio and Tobira to merge
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 8:42AM CST
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02)
Medtronic Starts Cyro-FIRST Trial for AF Patients, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 1:40PM CST
Management at Medtronic (MDT) expects the AF patient population to expand exponentially over the next generation. Consequently, the cryoballoon ablation therapy should be able to garner high demand.
MGNX: 34.09 (+0.10), ICUI: 88.98 (+0.42), MDT: 75.26 (+0.33), CNAT: 5.92 (+0.10)
Conatus Announced Results from Emricasan Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 4:10PM CST
Conatus (CNAT) announced top-line results from studies on emricasan in organ-impaired patients.
CNAT: 5.92 (+0.10), AMGN: 153.48 (+0.30), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Targeting the Enemies of the Largest Organ in the Human Body: Conatus Pharmaceuticals Analyst Report by Caprock Research and Issued By BrokerBank Securities, Inc.
PR Newswire - Mon Jan 12, 6:00AM CST
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) - The liver is the largest organ in the human body and it is responsible for many crucial metabolic functions, including the regulation of lipid and sugar metabolism, protein production for proteins involved with blood clotting, and the purification of blood. There are over 100 described diseases of the human liver which can be very debilitating and life-threatening, if not effectively treated. Liver diseases can result from HCV, HBV (hepatitis B virus), obesity, chronic excessive alcohol use, or autoimmune diseases. According to the National Institutes of Health (NIH) an estimated 5.5 million Americans have chronic liver disease or cirrhosis, while according to the European Association for the Study of the Liver, 29 million Europeans have chronic liver disease. One company targeting this large potential market is Conatus Pharmaceuticals Inc.
CNAT: 5.92 (+0.10)
Notes On Conatus Pharmaceuticals' ACLF (Liver Failure) Trial Report
Left Banker - at Seeking Alpha - Sat Jan 10, 7:46AM CST
CNAT: 5.92 (+0.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 11:47AM CST
EOPN: 8.55 (-0.01), ADHD: 6.92 (+0.73), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), FIVE: 33.01 (+0.11), TESO: 11.37 (+0.37), ALXA: 2.07 (+0.09), PRTO: 10.45 (unch), AGEN: 5.03 (-0.01), ARGS: 8.35 (-0.12), TOPS: 1.14 (+0.02), HILL: 4.42 (+0.06), EDAP: 3.55 (+0.13), CTSO: 8.20 (+0.18), VLCCF: 4.15 (-0.06), SCYX: 9.48 (+0.07), VIMC: 8.59 (-0.08), SBLK: 4.48 (+0.15), DCTH: 1.14 (+0.04), IDN: 1.43 (-0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 8:10AM CST
SD: 2.09 (+0.14), PTLA: 34.96 (+3.13), EOPN: 8.55 (-0.01), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), INFY: 36.60 (-0.13), FIVE: 33.01 (+0.11), AGEN: 5.03 (-0.01), SAN: 7.18 (+0.13), EDAP: 3.55 (+0.13), GMLP: 28.17 (+0.45), CTSO: 8.20 (+0.18), SBLK: 4.48 (+0.15), IDN: 1.43 (-0.01)
Conatus off big premarket
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 7:46AM CST
CNAT: 5.92 (+0.10)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 4:35PM CST
HELE: 77.94 (-0.34), EOPN: 8.55 (-0.01), RRTS: 25.41 (+0.02), CNAT: 5.92 (+0.10), JNUG: 30.90 (+1.14), RVNC: 16.84 (+0.27), AGI: 5.78 (+0.03), FIVE: 33.01 (+0.11), BARL: 19.19 (unch), SBLK: 4.48 (+0.15)
Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan
GlobeNewswire - Thu Jan 08, 3:06PM CST
- Pharmacokinetic/Pharmacodynamic Data and Clinical Observations Guide Development Pathway -
CNAT: 5.92 (+0.10)
St. Jude Medical Starts Enrolment for Ablation Catheter Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 1:10PM CST
Medical device company, St. Jude Medical Inc. (STJ), recently enrolled the first patient in the STAR-VT (Substrate Targeted Ablation using the FlexAbility Ablation Catheter System for the Reduction of Ventricular Tachycardia) clinical trial.
ICUI: 88.98 (+0.42), INSY: 51.50 (-0.66), CNAT: 5.92 (+0.10), STJ: 67.48 (+0.65)
Medtronic Initiates Study on Absorbable Antibacterial Envelope - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 12:50PM CST
Medtronic's (MDT) TYRX Absorbable Antibacterial Envelope has been designed to contain a CIED, in order to offer a stable environment when implanted in a patient's body.
ICUI: 88.98 (+0.42), INSY: 51.50 (-0.66), MDT: 75.26 (+0.33), CNAT: 5.92 (+0.10)
Conatus to Present at BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York at 8:30 a.m. ET on Tuesday, February 10, 2015. An audio webcast and a copy of the presentation will be available live and archived in the Investor Center of the company's website at http://ir.conatuspharma.com/events.cfm.
CNAT: 5.92 (+0.10)
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 6.80 (+0.03), RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
ResMed (RMD) Beats Q2 Earnings & Revenues, Margin Falls - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 8:00AM CST
Currently, ResMed (RMD) is engaged in executing its three horizons growth strategy of improving patient quality-of-life, lowering healthcare costs, and preventing chronic disease progression.
ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), CNAT: 5.92 (+0.10), RMD: 66.25 (+0.79)
Medtronic Unveils MiniMed 640G Advanced Glucose Sensor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 12:20PM CST
Medtronic's (MDT) MiniMed 640G System acts like an artificial pancreas by managing hypoglycemia and rebound hyperglycemia
ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), MDT: 75.26 (+0.33), CNAT: 5.92 (+0.10)
Conatus Pharmaceuticals Implements Veeva Vault eTMF and QualityDocs to Speed Global Clinical Trials of New Biologic Emricasan
Business Wire - Thu Jan 22, 6:00AM CST
To improve visibility, control, and collaboration for its ongoing and planned clinical trials, San Diego-based biotech Conatus Pharmaceuticals selected cloud-based Veeva Vault eTMF and Veeva Vault QualityDocs - applications for the management of clinical study and quality and development documentation, respectively. As the company expanded its network of external partners across a growing number of sites worldwide, Conatus sought a fully paperless solution to reduce costs and provide an efficient way for all parties - including a largely mobile clinical workforce - to access content. With Veeva Vault eTMF and Veeva Vault QualityDocs, Conatus has gained a single, authoritative source for verified, current documents, streamlining information sharing across the enterprise.
VEEV: 30.12 (+0.17), CNAT: 5.92 (+0.10)
Abaxis' (ABAX) VetScan Feline Test Wins USDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 12:50PM CST
Abaxis' novel test kit is used to identify the presence of FeLV antigen and FIV antibodies in blood samples of cats.
ICUI: 88.98 (+0.42), ABAX: 60.93 (+0.65), CNAT: 5.92 (+0.10), VASC: 26.44 (+0.79)
Trial Data Add Little Clarity And Much Confusion To Conatus
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 21, 9:39AM CST
CNAT: 5.92 (+0.10)
St. Jude Medical (STJ) Announces Preliminary Q4 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 11:00AM CST
St. Jude Medical, Inc.'s (STJ) fourth-quarter revenues are estimated to grow 1% year over year to around $1.44 billion, which is in line with the current Zacks Consensus Estimate.
ICUI: 88.98 (+0.42), CNAT: 5.92 (+0.10), STJ: 67.48 (+0.65), OSUR: 8.13 (+0.06)
Regado Bio and Tobira to merge
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 8:42AM CST
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02)
Medtronic Starts Cyro-FIRST Trial for AF Patients, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 1:40PM CST
Management at Medtronic (MDT) expects the AF patient population to expand exponentially over the next generation. Consequently, the cryoballoon ablation therapy should be able to garner high demand.
MGNX: 34.09 (+0.10), ICUI: 88.98 (+0.42), MDT: 75.26 (+0.33), CNAT: 5.92 (+0.10)
Conatus Announced Results from Emricasan Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 4:10PM CST
Conatus (CNAT) announced top-line results from studies on emricasan in organ-impaired patients.
CNAT: 5.92 (+0.10), AMGN: 153.48 (+0.30), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Targeting the Enemies of the Largest Organ in the Human Body: Conatus Pharmaceuticals Analyst Report by Caprock Research and Issued By BrokerBank Securities, Inc.
PR Newswire - Mon Jan 12, 6:00AM CST
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) - The liver is the largest organ in the human body and it is responsible for many crucial metabolic functions, including the regulation of lipid and sugar metabolism, protein production for proteins involved with blood clotting, and the purification of blood. There are over 100 described diseases of the human liver which can be very debilitating and life-threatening, if not effectively treated. Liver diseases can result from HCV, HBV (hepatitis B virus), obesity, chronic excessive alcohol use, or autoimmune diseases. According to the National Institutes of Health (NIH) an estimated 5.5 million Americans have chronic liver disease or cirrhosis, while according to the European Association for the Study of the Liver, 29 million Europeans have chronic liver disease. One company targeting this large potential market is Conatus Pharmaceuticals Inc.
CNAT: 5.92 (+0.10)
Notes On Conatus Pharmaceuticals' ACLF (Liver Failure) Trial Report
Left Banker - at Seeking Alpha - Sat Jan 10, 7:46AM CST
CNAT: 5.92 (+0.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 11:47AM CST
EOPN: 8.55 (-0.01), ADHD: 6.92 (+0.73), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), FIVE: 33.01 (+0.11), TESO: 11.37 (+0.37), ALXA: 2.07 (+0.09), PRTO: 10.45 (unch), AGEN: 5.03 (-0.01), ARGS: 8.35 (-0.12), TOPS: 1.14 (+0.02), HILL: 4.42 (+0.06), EDAP: 3.55 (+0.13), CTSO: 8.20 (+0.18), VLCCF: 4.15 (-0.06), SCYX: 9.48 (+0.07), VIMC: 8.59 (-0.08), SBLK: 4.48 (+0.15), DCTH: 1.14 (+0.04), IDN: 1.43 (-0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 8:10AM CST
SD: 2.09 (+0.14), PTLA: 34.96 (+3.13), EOPN: 8.55 (-0.01), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), INFY: 36.60 (-0.13), FIVE: 33.01 (+0.11), AGEN: 5.03 (-0.01), SAN: 7.18 (+0.13), EDAP: 3.55 (+0.13), GMLP: 28.17 (+0.45), CTSO: 8.20 (+0.18), SBLK: 4.48 (+0.15), IDN: 1.43 (-0.01)
Conatus off big premarket
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 7:46AM CST
CNAT: 5.92 (+0.10)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 4:35PM CST
HELE: 77.94 (-0.34), EOPN: 8.55 (-0.01), RRTS: 25.41 (+0.02), CNAT: 5.92 (+0.10), JNUG: 30.90 (+1.14), RVNC: 16.84 (+0.27), AGI: 5.78 (+0.03), FIVE: 33.01 (+0.11), BARL: 19.19 (unch), SBLK: 4.48 (+0.15)
Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan
GlobeNewswire - Thu Jan 08, 3:06PM CST
- Pharmacokinetic/Pharmacodynamic Data and Clinical Observations Guide Development Pathway -
CNAT: 5.92 (+0.10)
St. Jude Medical Starts Enrolment for Ablation Catheter Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 1:10PM CST
Medical device company, St. Jude Medical Inc. (STJ), recently enrolled the first patient in the STAR-VT (Substrate Targeted Ablation using the FlexAbility Ablation Catheter System for the Reduction of Ventricular Tachycardia) clinical trial.
ICUI: 88.98 (+0.42), INSY: 51.50 (-0.66), CNAT: 5.92 (+0.10), STJ: 67.48 (+0.65)
Medtronic Initiates Study on Absorbable Antibacterial Envelope - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 12:50PM CST
Medtronic's (MDT) TYRX Absorbable Antibacterial Envelope has been designed to contain a CIED, in order to offer a stable environment when implanted in a patient's body.
ICUI: 88.98 (+0.42), INSY: 51.50 (-0.66), MDT: 75.26 (+0.33), CNAT: 5.92 (+0.10)
